Long-term risk of prostate cancer mortality among men with baseline prostate-specific antigen below 3 ng/ml: evidence from the finnish randomized study of screening for prostate cancer
Background and objective - Despite the evidence for prostate-specific antigen (PSA) screening reducing prostate cancer (PCa) mortality, the optimal PSA cutoff and the clinical significance of low initial PSA levels in predicting long-term PCa mortality remain subjects of ongoing research. We assesse...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
April 2025
|
| In: |
European urology oncology
Year: 2025, Volume: 8, Issue: 2, Pages: 452-459 |
| ISSN: | 2588-9311 |
| DOI: | 10.1016/j.euo.2024.11.010 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.euo.2024.11.010 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2588931124002724 
|
| Author Notes: | Idris O. Ola, Kirsi Talala, Teuvo Tammela, Kimmo Taari, Teemu J. Murtola, Paula Kujala, Jani Raitanen, Anssi Auvinen |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1937502198 | ||
| 003 | DE-627 | ||
| 005 | 20251120193456.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251001s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.euo.2024.11.010 |2 doi | |
| 035 | |a (DE-627)1937502198 | ||
| 035 | |a (DE-599)KXP1937502198 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Ola, Idris |e VerfasserIn |0 (DE-588)1352849062 |0 (DE-627)191379685X |4 aut | |
| 245 | 1 | 0 | |a Long-term risk of prostate cancer mortality among men with baseline prostate-specific antigen below 3 ng/ml |b evidence from the finnish randomized study of screening for prostate cancer |c Idris O. Ola, Kirsi Talala, Teuvo Tammela, Kimmo Taari, Teemu J. Murtola, Paula Kujala, Jani Raitanen, Anssi Auvinen |
| 264 | 1 | |c April 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 6. Dezember 2024, Artikelversion: 20. März 2025 | ||
| 500 | |a Gesehen am 01.10.2025 | ||
| 520 | |a Background and objective - Despite the evidence for prostate-specific antigen (PSA) screening reducing prostate cancer (PCa) mortality, the optimal PSA cutoff and the clinical significance of low initial PSA levels in predicting long-term PCa mortality remain subjects of ongoing research. We assessed PCa mortality among men with initial PSA levels below 3 ng/ml during the first screening round of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). - Methods - A retrospective cohort study was conducted, including 20 268 men from the screening arm of the FinRSPC with an initial PSA level of <3 ng/ml, with follow-up spanning up to 20 yr. Hazard ratios (HRs) and their 95% corresponding confidence intervals (CIs) were estimated using a Cox regression analysis. - Key findings and limitations - During a median follow-up of 17.8 yr, 1840 PCa cases were diagnosed and 128 PCa deaths occurred, with the cumulative PCa mortality of 0.6% and a mortality rate of four per 10 000 person-years. PCa mortality was five-fold higher at PSA levels of 2-2.99 ng/ml (HR 5.0, 95% CI 3.1-8.1) than at <1 ng/ml. Deaths from cases with Gleason score <7 and European Association of Urology low-risk group tumors showed a stronger association with PSA, particularly in the 2-2.99 ng/ml range versus <1 ng/ml. Additionally, PCa mortality in younger men (55-58 yr at entry) exhibited a stronger association with PSA than that in older men (67-71 yr at baseline). Addition of the cumulative number of PSA tests slightly improved the overall prediction of PCa death based on Harrell’s C-statistic (base model 0.683 vs 0.717). The relatively small number of deaths, particularly among men with low-risk disease, may potentially limit the statistical precision of the results. - Conclusions and clinical implications - Our findings highlight the importance of a nuanced approach to PSA in PCa screening, suggesting utility for combining PSA with other tests at low levels and indicating minimal risk associated with discontinuing screening at ages 67-71 yr when PSA is low. - Patient summary - In this study, we analyzed prostate cancer deaths in Finnish men with low initial prostate-specific antigen (PSA) levels. We found that the risk of prostate cancer death increases in relation to PSA, especially in younger men. Screening might safely be stopped at ages 67-71 yr if PSA remains low. | ||
| 650 | 4 | |a Cancer epidemiology | |
| 650 | 4 | |a Cancer screening | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 4 | |a Prostate cancer mortality | |
| 650 | 4 | |a Prostate-specific antigen | |
| 650 | 4 | |a Randomized controlled trials | |
| 700 | 1 | |a Talala, Kirsi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tammela, Teuvo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Taari, Kimmo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Murtola, Teemu J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kujala, Paula |e VerfasserIn |4 aut | |
| 700 | 1 | |a Raitanen, Jani |e VerfasserIn |4 aut | |
| 700 | 1 | |a Auvinen, Anssi |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European urology oncology |d Amsterdam : Elsevier, 2018 |g 8(2025), 2 vom: Apr., Seite 452-459 |h Online-Ressource |w (DE-627)1032696346 |w (DE-600)2945338-0 |w (DE-576)511878028 |x 2588-9311 |7 nnas |a Long-term risk of prostate cancer mortality among men with baseline prostate-specific antigen below 3 ng/ml evidence from the finnish randomized study of screening for prostate cancer |
| 773 | 1 | 8 | |g volume:8 |g year:2025 |g number:2 |g month:04 |g pages:452-459 |g extent:8 |a Long-term risk of prostate cancer mortality among men with baseline prostate-specific antigen below 3 ng/ml evidence from the finnish randomized study of screening for prostate cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.euo.2024.11.010 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2588931124002724 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251001 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1352849062 |a Ola, Idris |m 1352849062:Ola, Idris |d 50000 |e 50000PO1352849062 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1937502198 |e 4778543815 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"title":[{"title":"European urology oncology","title_sort":"European urology oncology"}],"part":{"volume":"8","text":"8(2025), 2 vom: Apr., Seite 452-459","extent":"8","year":"2025","pages":"452-459","issue":"2"},"pubHistory":["Volume 1, issue 1 (May 2018)-"],"language":["eng"],"recId":"1032696346","disp":"Long-term risk of prostate cancer mortality among men with baseline prostate-specific antigen below 3 ng/ml evidence from the finnish randomized study of screening for prostate cancerEuropean urology oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"eki":["1032696346"],"zdb":["2945338-0"],"issn":["2588-9311"]},"origin":[{"publisherPlace":"Amsterdam","publisher":"Elsevier","dateIssuedDisp":"[2018]-"}],"name":{"displayForm":["European Association of Urology"]},"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"noteIll":"Illustrationen","extent":"8 S."}],"id":{"eki":["1937502198"],"doi":["10.1016/j.euo.2024.11.010"]},"origin":[{"dateIssuedDisp":"April 2025","dateIssuedKey":"2025"}],"name":{"displayForm":["Idris O. Ola, Kirsi Talala, Teuvo Tammela, Kimmo Taari, Teemu J. Murtola, Paula Kujala, Jani Raitanen, Anssi Auvinen"]},"language":["eng"],"recId":"1937502198","note":["Online verfügbar: 6. Dezember 2024, Artikelversion: 20. März 2025","Gesehen am 01.10.2025"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Long-term risk of prostate cancer mortality among men with baseline prostate-specific antigen below 3 ng/ml","subtitle":"evidence from the finnish randomized study of screening for prostate cancer","title":"Long-term risk of prostate cancer mortality among men with baseline prostate-specific antigen below 3 ng/ml"}],"person":[{"role":"aut","display":"Ola, Idris","roleDisplay":"VerfasserIn","given":"Idris","family":"Ola"},{"given":"Kirsi","family":"Talala","role":"aut","roleDisplay":"VerfasserIn","display":"Talala, Kirsi"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Tammela, Teuvo","given":"Teuvo","family":"Tammela"},{"roleDisplay":"VerfasserIn","display":"Taari, Kimmo","role":"aut","family":"Taari","given":"Kimmo"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Murtola, Teemu J.","given":"Teemu J.","family":"Murtola"},{"family":"Kujala","given":"Paula","display":"Kujala, Paula","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","display":"Raitanen, Jani","roleDisplay":"VerfasserIn","given":"Jani","family":"Raitanen"},{"display":"Auvinen, Anssi","roleDisplay":"VerfasserIn","role":"aut","family":"Auvinen","given":"Anssi"}]} | ||
| SRT | |a OLAIDRISTALONGTERMRI2025 | ||